Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma

Medical experts give an overview of relapsed/refractory multiple myeloma, focusing on diagnosis and current management strategies

Experts give an overview of long-term follow-up efficacy data from the MonumenTAL-1 study.

Experts give an overview of safety data from the MonumenTAL-1 study.

Experts address the unique challenges in managing adverse events associated with GPRC5D therapies compared to other cancer treatments, while Samantha will discuss strategies for preparing and educating patients undergoing GPRC5D therapy.

Experts explain the administration of step-up and treatment doses for GPRC5D at your institution, including whether they are given in clinic or in the community, and will discuss how patients are monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during the step-up phase.

Experts explore additional toxicities observed with B-cell maturation antigen–targeting bispecifics, such as infections, neurotoxicity, and hematological issues, and discuss how these are managed in practice.

Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.

Experts provide advice to patients and caregivers on managing oral and skin toxicities.